Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results

Gilead Sciences US3755581036

Shares of Gilead Sciences are consolidating near the $120 level following significant clinical and financial developments. The company announced that its investigational once-daily oral combination of bictegravir and lenacapavir successfully met the primary endpoint in the Phase 3 ARTISTRY-2 trial. This news has prompted several analyst upgrades and comes on the heels of a strong quarterly earnings report.

Gilead’s recent third-quarter results exceeded market expectations, posting earnings per share (EPS) of $2.47 against estimates of $2.16. Consequently, the company raised its full-year 2025 EPS guidance to a range of $8.05 to $8.25. The firm also maintains a robust dividend, with a payout of $0.79 per share scheduled for December 30, 2025, translating to a yield of approximately 2.6%.